Clinical trials: Psoriatic Arthritis, open to volunteers
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
- Trial name
- NCT06668181
- Testing
- Bimekizumab
- Where
- 23 sites in Canada, France and 4 more
- Volunteers
- 40 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
Combined High-Intensity Aerobic Training and Resistance Training in Psoriatic Arthritis
The goal of this randomised controlled trial is to evaluate the effects of a 12-week intervention comprising high-intensity interval aerobic training and strength training on cardiovascular function, metabolic health profile and…
- Trial name
- PsA-HIIT (NCT07352696)
- Testing
- Exercise program
- Where
- 2 sites in Sweden
- Volunteers
- 88 people
- Sponsor
- Vastra Gotaland Region
Rheumatic Joint Disease
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies.
- Trial name
- NCT02418442
- Where
- 82 sites in United States, Canada and 3 more
- Volunteers
- 20,000 people
- Sponsor
- Duke University
Active Juvenile Psoriatic Arthritis
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
- Trial name
- PEAPOD (NCT04804553)
- Testing
- Apremilast
- Where
- 44 sites in Belgium, France and 12 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Arthritis, Psoriatic (PsA), Arthritis, Rheumatoid (RA)
Patient-Reported Outcomes Dashboard With Goal Setting to Support Shared Decision-Making in Inflammatory Arthritis
The goal of this clinical trial is to learn whether showing patient-reported symptoms and personal treatment goals to rheumatology clinicians on a dashboard in the electronic health record improves shared decision-making for…
- Trial name
- NCT07865390
- Testing
- Patient-Reported Outcomes Dashboard With Goal Setting
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Northwestern University
Psoriatic Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
- Trial name
- NCT06671483
- Testing
- Zasocitinib, Active Comparator
- Where
- 188 sites in United States, Belgium and 18 more
- Volunteers
- 1,088 people
- Sponsor
- Takeda
Juvenile Psoriatic Arthritis
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
- Trial name
- NCT06751238
- Testing
- Secukinumab
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Psoriatic Arthritis
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
The purpose of this Phase 2a/b study is: 1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with psoriatic arthritis (PsA). 2.
- Trial name
- NCT07801495
- Testing
- DDY391
- Where
- 3 sites in United States
- Volunteers
- 220 people
- Sponsor
- Novartis Pharmaceuticals
Arthritic Psoriasis, Psoriasis (PsO)
Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study.
In terms of blood flow per unit of tissue, the retina is one of the tissues with the highest blood flow in the body. Parameters such as the thickness of the choroid layer, which plays a crucial role in maintaining normal eye…
- Conditions
- Arthritic Psoriasis, Psoriasis (PsO), Retinal Vessels
- Trial name
- PsA-RETINA (NCT07858591)
- Testing
- OCTA-SCP, OCTA-DCP, OCTA-RPC
- Where
- Turkey (Türkiye)
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Psoriatic Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
- Trial name
- NCT07871721
- Testing
- Zasocitinib
- Volunteers
- 644 people
- Sponsor
- Takeda
Psoriatic Arthritis (PsA)
Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis
This study will investigate if the study medicine FT2109 can treat symptoms of active Psoriatic Arthritis (PsA). This study assesses the safety and efficacy of FT2109 in adult participants with active PsA who may or may not have…
- Trial name
- NCT07869134
- Testing
- FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2
- Volunteers
- 210 people
- Sponsor
- Forward Therapeutics
Juvenile Psoriatic Arthritis
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
- Trial name
- NCT06869551
- Testing
- Deucravacitinib
- Where
- 48 sites in United States, Brazil and 9 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Autoimmune Disease, Crohn Disease
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in…
- Conditions
- Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT03816345
- Testing
- Biospecimen Collection, Cabozantinib, Fluoropyrimidine
- Where
- 52 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Psoriasis, Colitis, Ulcerative
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the…
- Conditions
- Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
- Trial name
- NCT07654751
- Testing
- Breast Milk Sample Collection, Guselkumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis, Psoriatic Arthritis
Modifying PEST for Psoriatic Arthritis Screening
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
- Trial name
- ScreenX (NCT06382051)
- Testing
- PEST Screening group
- Where
- 30 sites in Canada
- Volunteers
- 502 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Crohns Disease, Colitis, Ulcerative
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile…
- Conditions
- Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
- Trial name
- TRILOGY (NCT06663332)
- Testing
- Guselkumab
- Where
- 51 sites in United States, Argentina and 15 more
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Psoriatic
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in…
- Trial name
- ICONIC-PsA 2 (NCT06807424)
- Testing
- Icotrokinra
- Where
- 236 sites in United States, Argentina and 22 more
- Volunteers
- 750 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red…
- Trial name
- GURU (NCT07220824)
- Where
- 21 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Psoriatic
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA).
- Trial name
- VELOTA (NCT07321873)
- Testing
- JNJ-88545223
- Where
- 75 sites in United States, China and 6 more
- Volunteers
- 240 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Psoriatic
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes…
- Trial name
- PEGASUS (NCT07532226)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Janssen-Cilag Ltd.